我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
95
7 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
3
3.2%
已完成
50
52.6%
Enrolling By Invitation
2
2.1%
尚未招募
招募中
7
7.4%
终止
4
4.2%
Unknown
27
28.4%
暂无批准数据
- 4DMedical has received FDA 510(k) clearance for CT:VQ, the world's first non-contrast CT-based ventilation-perfusion imaging software that eliminates the need for radioactive tracers. - The technology transforms standard chest CT scans into quantitative lung function maps using existing CT infrastructure, opening access to over 14,500 scanners across the US. - CT:VQ addresses a potential US market worth over $1.1 billion annually, with CMS confirming reimbursement under Category III CPT codes. - Clinical validation showed strong agreement with nuclear medicine SPECT scans while providing clearer images and faster results for diagnosing pulmonary conditions.
